Entering text into the input field will update the search result below

Anestagel Superior To Exparel In Pre-Clinical Study

Jan. 26, 2017 2:24 PM ETPCRX1 Comment
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

ST. PAUL, Minn., Jan. 25, 2017 /PRNewswire/ -- InSitu Biologics, LLC ("InSitu" or "the Company"), an emerging drug delivery company focusing on development of new and proprietary treatments using its Matrix™ BioHydrogel, today announced results from recent pre-clinical studies for their lead product, AnestaGel™. AnestaGel is a long-lasting and long-acting non-opiate painkiller, targeted for use in peri-operative regional pain management.

In a series of independent tests performed under GLP regulations, comparing operative site injections of AnestaGel and EXPAREL® from Pacira, Inc., AnestaGel was proven to last longer, and provide a greater analgesic effect than EXPAREL. In a separate test that determines the PharmacoKinetic(PK) effect for the painkiller bupivacaine, which is used in both AnestaGel and EXPAREL, bupivacaine was proven to be released from AnestaGel into the blood up to 96-120 hours after injection exceeding the presence of bupivacaine in the blood from both EXPAREL and straight bupivacaine injections.

"As we had hypothesized going in to these studies, we expected that AnestaGel would perform very well when compared to the non-opiate products available today," said Dr. Jake Hutchins, Director of the Regional Anesthesia Acute Pain and Ambulatory Surgery division at the University of Minnesota, and the Pre-Clinical Study Director for InSitu Biologics. James Segermark, CEO of InSitu added, "Early on we believed that AnestaGel could be tuned to act as a short-term reservoir, essentially a non-pulsatile organ, and that is what we have now verified and validated. We look forward to the next steps that will bring this predictable, very long-acting, non-opiate product to patients that face the prospect of post-surgical pain." The Company believes that AnestaGel could be used in three distinct markets for peri-operative pain management that represent nearly $31 billion in annual revenue in the US.

AnestaGel uses a novel approach to delivering sustained-released analgesics into the target tissue via the Matrix, which is a tunable, biocompatible, and pH neutral platform. This allows AnestaGel to provide target site-specific, non-migratory placement, a flexible and high dose drug-load reservoir capacity, and a tunable and predictable pharmacological effect.

About InSitu:

InSitu Biologics develops and manufactures implantable timed release products composed of our proprietary tunable, bio-polymeric hydrogel, Matrix™. We are currently pursuing applications for delivery in soft and bone tissue(s). For more information, please contact James Segermark, CEO, at (651) 289-6444 or visit www.insitubiologics.com.

InSitu Biologics, LLC makes no representations or warranties, express or implied, regarding the accuracy or completeness of the information contained herein. Trademarks are the owners of their respective owners.

Supporting Documents

  1. InsituBiologics_WhitePaper-FINAL_6-29-16docx-1.pdf

Analyst's Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Co Founder, Medical Advisor, InSitu Biologics

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.